Avant Immunotherapeutics stands to receive at least $50 million from an agreement with Pfizer for the development of CDX-110, an experimental brain cancer vaccine. The drugmakers plan to test CDX-110 -- acquired by Avant after finalizing a merger with Celldex Therapeutics -- for other cancers, including breast, ovarian, advanced prostate and colorectal cancer.

Related Summaries